WO2024064091 - NOVEL PYRIMIDINE COMPOUND AS KINASE INHIBITORS WITH BIOLOGICAL ACTIVITIES ON EGFR MUTANTS
National phase entry:
Publication Number
WO/2024/064091
Publication Date
28.03.2024
International Application No.
PCT/US2023/033057
International Filing Date
18.09.2023
Title **
[English]
NOVEL PYRIMIDINE COMPOUND AS KINASE INHIBITORS WITH BIOLOGICAL ACTIVITIES ON EGFR MUTANTS
[French]
NOUVEAU COMPOSÉ DE PYRIMIDINE UTILISÉ EN TANT QU'INHIBITEURS DE KINASES À ACTIVITÉS BIOLOGIQUES SUR DES MUTANTS D'EGFR
Applicants **
ADVENCHEN PHARMACEUTICALS, LLC
887 Patriot Drive, STE A
Moorpark, CA 93021, US
Inventors
CHEN, Guoqing, Paul
887 Patriot Drive, STE A
Moorpark, CA 93021, US
LI, Zhe
887 Patriot Drive, STE A
Moorpark, CA 93021, US
ZHANG, Wenchao
887 Patriot Drive, STE A
Moorpark, CA 93021, US
YAN, Changren
887 Patriot Drive, STE A
Moorpark, CA 93021, US
Priority Data
63/376,253
19.09.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1118 | |
| EPO | Filing, Examination | 6855 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4005 |
Total: 13084 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
This present invention relates to compounds of Formula I that feature the inhibition of protein tyrosine kinases (PTKs), including EGFR mutants, their pharmaceutical compositions that comprising a therapeutically effective amount of the corresponding compounds and methods of use therefor.[French]
La présente invention concerne des composés de formule I qui permettent l'inhibition de protéines tyrosine kinases (PTK), notamment de mutants d'EGFR, leurs compositions pharmaceutiques qui comprennent une quantité thérapeutiquement efficace des composés correspondants et leurs procédés d'utilisation.